You are here

NASDAQ

Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience

Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience

BioSpace

Flag link:

Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

Antibody biotech Abpro taps SPAC to get back on Nasdaq track 5 years after axed IPO

Fierce Biotech

Flag link:

Device company HDL Therapeutics eyes public listing in $480m SPAC deal

Device company HDL Therapeutics eyes public listing in $480m SPAC deal

Pharmaphorum

HDL Therapeutics

atherosclerotic plaques

Flag link:

Okyo Pharma withdraws offer to sell shares after just 3 days citing 'changing market conditions'

Okyo Pharma withdraws offer to sell shares after just 3 days citing 'changing market conditions'

Fierce Biotech

Flag link:

Apogee, Sagimet overshoot IPO expectation as both biotechs land on Nasdaq

Apogee, Sagimet overshoot IPO expectation as both biotechs land on Nasdaq

Fierce Biotech

Apogee Therapeutics

Sagimet Biosciences

Flag link:

South Korean biotech group spies US SPAC as route to Nasdaq

South Korean biotech group spies US SPAC as route to Nasdaq

Fierce Biotech

Flag link:

Turnstone Biologics Files for $86M IPO Amid Financial Difficulties

Turnstone Biologics Files for $86M IPO Amid Financial Difficulties

BioSpace

Turnstone Biologics

Flag link:

Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer

Biotech consolidation continues as Nasdaq-listed Erytech merges with phage therapy developer

Endpoints

Flag link:

Moderna Gets Good News, but Another Biotech Stock Is Falling Again

Moderna Gets Good News, but Another Biotech Stock Is Falling Again

Motley Fool

Moderna Therapeutics

Flag link:

Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move

Elicio uses struggling Angion as route to Nasdaq ahead of cancer vaccine's phase 2 move

Fierce Biotech

Elicio Therapeutics

cancer vaccines

clinical trials

Angion Biomedica

Flag link:

GE’s board finalizes healthcare spinoff

GE’s board finalizes healthcare spinoff

Medtech Dive

Flag link:

Three Biopharma Companies Heading to Nasdaq Through SPACs

Three Biopharma Companies Heading to Nasdaq Through SPACs

BioSpace

Flag link:

Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner

Vaccine Stocks Are Rising, but This Biotech Is Monday's Big Nasdaq Winner

Motley Fool

Moderna Therapeutics

Intra-Cellular Therapies

Flag link:

Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug

Amylyx takes its ALS program to Nasdaq, raising the stakes for the biotech's only drug

Endpoints

Flag link:

Italian cancer gene therapy biotech makes history with modest Nasdaq IPO

Italian cancer gene therapy biotech makes history with modest Nasdaq IPO

Endpoints

Flag link:

Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut

Vaxxinity, hoping to turn bodies into their own drug factories, makes a subdued Wall Street debut

Fierce Biotech

Flag link:

First Day Trading a Letdown for LianBio in Shadow of Beijing Market Crackdown

First Day Trading a Letdown for LianBio in Shadow of Beijing Market Crackdown

BioSpace

Flag link:

Two Biopharmas Nix IPO Plans in Unstable Market

Two Biopharmas Nix IPO Plans in Unstable Market

BioSpace

Flag link:

OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO

OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO

Endpoints

Theseus Pharmaceuticals

Flag link:

Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record

Three more biotechs hit Nasdaq as the sector, now with more than $13B raised, continues barreling toward record

Endpoints

Pasithea Therapeutics

Tyra Biosciences

DiCE Therapeutics

Flag link:

Pages